Analysis of anti-infection therapeutic schedule analysis for neonatal Streptococcus agalactiae meningitis and discussion on the indications for drug withdrawal  

新生儿无乳链球菌脑膜炎的抗感染治疗方案分析及停药指征探讨

作　　者：Haiyan Wu Tao Wang Qian Wang Lin Tang 武海艳;王涛;王倩;唐琳(山东第一医科大学附属中心医院药学部,山东济南250013;山东第一医科大学附属省立医院药学部,山东济南250021;山东第一医科大学附属中心医院精益项目管理办公室,山东济南250013)

机构地区：[1]Department of Pharmacy,Central Hospital Affiliated to Shandong First Medical University,Jinan 250013,Shandong,China [2]Department of Pharmacy,Shandong Provincial Hospital A ffiliated to Shandong First Medical University,Jinan 250021,Shandong,China [3]Department of Lean Project Management,Central Hospital Affiliated to Shandong First Medical University,Jinan 250013,Shandong,China

出　　处：《Journal of Chinese Pharmaceutical Sciences》2021年第8期686-691,共6页中国药学（英文版）

摘　　要：The clinical manifestations of neonatal GBS meningitis are as follows:non-specificity,long hospital stay,easy to cause neurological complications,and sequelae.Clinical pharmacist participated in the anti-infective treatment of a neonatal Streptococcus agalactiae meningitis whose cerebrospinal fluid was still abnormal when the drug was stopped.According to the PK/PD characteristics of antibacterial drugs,the permeability of the blood-brain barrier,and the adjustment of the antibiotic dose,the reasons for the decrease in the number of cerebrospinal fluid cells after vancomycin treatment were analyzed.Clinical pharmacists also analyzed the efficacy of linezolid in the treatment of neonatal bacterial meningitis,and discussed the indications for stopping medication when the cerebrospinal fluid is abnormal,so as to improve the safety and effectiveness of antibiotics in the treatment of neonatal bacterial meningitis.新生儿GBS脑膜炎的临床表现为:非特异性、住院时间长、易引起神经系统并发症和后遗症。临床药师参与一例停药时脑脊液仍异常的新生儿无乳链球菌脑膜炎的抗感染治疗。根据抗菌药物PK/PD特性、血脑屏障通透性、抗生素的剂量调整,分析脑脊液细胞数在使用万古霉素治疗后先降低后上升的原因,分析利奈唑胺治疗新生儿细菌性脑膜炎的疗效,探讨脑脊液异常时停药的适应症,以提高新生儿细菌性脑膜炎用药的安全性和有效性。

关 键 词：Streptococcus agalactiae meningitis VANCOMYCIN LINEZOLID Drug withdrawal indications Literature analysis 

分 类 号：R969[医药卫生—药理学]